Target the source, not just the symptoms1,2

AYVAKIT is designed to target KIT D816V, the underlying driver of ISM in ~95% of patients1-5

AYVAKIT is a tyrosine kinase inhibitor (TKI) designed for potent and selective inhibition of KIT D816V. AYVAKIT demonstrated greater inhibitory potency for KIT D816V vs wild type KIT in cellular assays.1

Symptom-directed therapies (SDT) alone may not be enough1,2

SDT may help address ISM symptoms but do not treat the underlying cause of the symptoms, the KIT D816V mutation. AYVAKIT inhibits the autophosphorylation of KIT in cellular assays, which ultimately blocks overproduction of abnormal and hyperactive mast cells thought to cause the symptoms of ISM.

Discover how AYVAKIT targets the underlying cause of ISM at the source— the KIT D816V mutation1,2,6-8

How AYVAKIT® (avapritinib) targets the KIT D816V mutation

ISM=indolent systemic mastocytosis; KIT=KIT proto-oncogene, receptor tyrosine kinase.

Consider targeting the cause of the symptoms
when treating ISM1,6,8

See how AYVAKIT was studied in ISM

PIONEER STUDY DESIGN

Patient portrayal

Indolent systemic mastocytosis patient and caregiver

References: 1. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; November 2024. 2. Pardanani A. Am J Hematol. 2023;98(7):1097-1116. 3. Kristensen T et al. Am J Hematol. 2014;89(5):493-498. 4. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 5. Ungerstedt  J et al. Cancers. 2022;14(16):3942. 6. Gülen T et al. J Intern Med. 2016;279(3):211-228. 7. Theoharides TC et al. N Engl J Med. 2015;373(2):163-172. 8. Akin C, ed. Mastocytosis: A Comprehensive Guide. Springer; 2020.